Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

220 results about "Single-photon emission computed tomography" patented technology

<ul><li>The scanned images contain light or dark areas depending on how much radioactive tracer was absorbed.</li><li>The radiologist interprets the scan, reports the findings, and sends it over to the referring physician.</li><li>The report may provide information about which areas of the brain are more active, or if the heart is receiving an adequate blood flow.</li><li>It could show blockage in the coronary artery, and detect hidden bone fractures.</li></ul>

Multimodal silica-based nanoparticles

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.
Owner:SLOAN KETTERING INST FOR CANCER RES +1

Stereoselective Synthesis of Amino Acid Analogs for Tumor Imaging

InactiveUS20060292073A1Maximum service lifeOrganic compound preparationSulfonic acid esters preparation1-amino-3-fluorocyclobutane-1-carboxylic acidCyclobutane
The radiolabeled non-natural amino acid 1-amino-3-cyclobutane-1-carboxylic acid (ACBC) and its analogs are candidate tumor imaging agents useful for positron emission tomography and single photon emission computed tomography due to their selective affinity for tumor cells. The present invention provides methods for stereo-selective synthesis of syn-ACBC analogs. The disclosed synthetic strategy is reliable and efficient and can be used to synthesize a gram quantity of various syn-isomers of the ACBC analogs, particularly, syn-[18F]-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC) and syn-[123I]-1-amino-3-iodocyclobutane-1-carboxylic (IACBC) acid analogs.
Owner:EMORY UNIVERSITY

Breast diagnostic apparatus for fused SPECT, PET, x-ray CT, and optical surface imaging of breast cancer

InactiveUS20060239398A1Improve spatial resolutionImprove system capabilitiesDiagnostics using lightPatient positioning for diagnosticsOptical reflectionImage-Guided Therapy
A new method of breast imaging to improve the detection of cancer during early stages of development is disclosed. The system combines molecular images of radioisotope uptake in cancerous cells with three dimensional high resolution single photon emission computed tomography (SPECT), positron emission tomography (PET), x-ray computed tomography (CT) and optical reflectance and emission (ORE) images of the breast. The system acquires data from nuclear isotopes within the breast and processes the data into three dimensional molecular tomographic images of cancerous cellular activity, morphological three dimensional x-ray density tomographic images and three dimensional optical surface images. These three sets of images or data are then combined to provide information as to the sensitivity and specificity as to the type of cancer present, three dimensional information as to the physical location of the cancer and reference information for radiologists, surgeons, oncologists and patients in order to plan stereo-tactic biopsy, minimally invasive surgery and image guided therapy, if necessary.
Owner:FUSED MULTIMODALITY IMAGING

Labeled 99mTc hydrazino-nicotinamide-dioxodecoyl-folic acid coordination compound and preparation method

The invention discloses a labeled 99mTc hydrazino-nicotinamide-dioxodecoyl-folic acid coordination compound with a general formula of 99mTc(HYNIC-NOON-FA)(Tricine)(L). In the structural formula, L is triphenyl sodium phosphate or triphenyl sodium photrisulfonic acid, wherein 1,8-diamido-3,6-octane dioxide is used as a connecting chain for generating a hydrazino-nicotinamide-3,6-dioxodecoyl-folic acid coupler respectively with folic acid and hydrazino-niacin through amido bonds and coordinating with oxygen atoms and phosphorus atoms in a co-ligand Tricine and an L molecule and 99mTc, and the 99mTc(HYNIC-NOON-FA)(Tricine)(L) coordination compound is obtained through two steps of: (a) synthesizing the hydrazino-nicotinamide-3,6-dioxodecoyl-folic acid coupler used as a ligand; and (b) labeling the 99mTc-hydrazino-nicotinamide-dioxodecoyl-folic acid coordination compound. The coordination compound has the advantages of high radiochemical purity, good stability, high tumor intake, good retention, low non-target organ background and clear tumor SPECT (Single Photon Emission Computed Tomography) development and can be prepared into a novel 99mTc labeled folic acid receptor tumor developer widely applied to the technical field of radioactive pharmaceutical chemistry and nuclear medicine.
Owner:BEIJING NORMAL UNIVERSITY +1

Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis

Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK irreversible inhibitors as their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are further disclosed.
Owner:T K SIGNAL

In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes

In vivo imaging may be used to assess a condition (e.g., a state of glaucoma or a state of ocular hypertension) of an eye of a living animal. A dye may be intravenously injected into the living animal. The dye may bind to amyloid in the nervous system of the animal. Images may be taken of a retina, an optic nerve head, an optic nerve, the lateral geniculate nucleus, and / or the visual cortex. Images may be taken using methods such as fluorescent angiography, magnetic resonance imaging, computed tomography, positron emission tomography, and / or single photon emission computed tomography. The condition of the eye and / or retinal ganglion cells in the eye may be assessed from one or more of the images. The condition of the eye may be assessed based on the presence of amyloid in one or more of the images.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Single photon emission computed tomography system

A single photon emission computed tomography system produces multiple tomographic images of the type representing a three-dimensional distribution of a photon-emitting radioisotope. The system has a base including a patient support for supporting a patient such that a portion of the patient is located in a field of view. A longitudinal axis is defined through the field of view. A detector module is adjacent the field of view and includes a photon-responsive detector. The detector is operable to detect if a photon strikes the detector. A photon-blocking member is positioned between the field of view and the detector. The blocking member has an aperture slot for passage of photons aligned with the aperture slot. A line of response is defined from the detector through the aperture. A collimating assembly includes a plurality of generally parallel collimating vanes formed of a photon attenuating material. The vanes are spaced apart so as to find a plurality of gaps, with the gaps each having a height. Each of the vanes has a front edge directed toward the field of view and a back edge directed towards the detector. The front-to-back depth of each of the vanes is greater than 10 times the height of the gaps. The plurality of vanes is disposed between the detector and the field of view such that only photons passing through one of the gaps can travel from the field of view to the detector. A displacement device moves either the detector module or the photon-blocking member relative to the other so that the aperture is displaced relative to the detector and the line of response is swept across at least a portion of the field of view.
Owner:HIGHBROOK HLDG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products